Oragenics has activated a second clinical site at Alfred Hospital for its Phase IIa trial of ONP-002, a drug candidate for treating concussion and mild traumatic brain injury (mTBI). The trial, already enrolling patients at Mackay Base Hospital in Australia, aims to enroll 40 patients to evaluate ONP-002's effectiveness in reducing brain inflammation and injury symptoms. This drug could become the first FDA-approved pharmacological treatment for concussion, addressing a significant unmet medical need. Data from this trial is expected by the end of 2026, supporting a planned Phase IIb trial in the U.S.
Yanik Guillemette, a Montreal-based entrepreneur and investment strategist, criticizes Canada's growing digital regulations, including the CRTC's proposal for streaming platforms to fund Canadian content. He argues these rules increase costs for cons...
Yanik Guillemette, a Canadian tech entrepreneur, criticizes Ottawa's increasing digital regulations, including a proposed 15% revenue tax on streaming platforms and laws C-11, C-18, and C-22. He argues these measures burden the tech ecosystem, raise ...
Sui, a blockchain project, announced it will implement private stablecoin transactions by default, allowing only senders and receivers to see transaction details. This privacy feature addresses a major hurdle for institutional users who require contr...
DeXe (DEXE) surged 11.16% to $15.21, topping today's crypto gainers amid growing interest in decentralized asset management. Other notable gainers include Stable (STABLE) up 9.31%, Morpho (MORPHO) up 5.62%, Venice Token (VVV) up 4.95%, and Provenance...
LexinFintech Holdings Ltd. announced its Q1 2026 unaudited results with total revenue rising 6.6% year-over-year to RMB3.3 billion and net income holding steady at RMB201 million despite a challenging macroeconomic environment. Loan originations incr...
